Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Sep 25;13(9):e0198074.
doi: 10.1371/journal.pone.0198074. eCollection 2018.

Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis

Ashwin Agarwal  1 , Russell P Hall 3rd  2 , Lionel L Bañez  3 , Adela R Cardones  2   3
Affiliations
Comparative Study

Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis

Ashwin Agarwal et al. PLoS One. .

Abstract

Background: Rituximab is a promising steroid sparing agent used in the treatment of moderate to severe pemphigus vulgaris. Its exact place in the algorithm of pemphigus treatment, vis-à-vis other, conventional adjuvant therapy (CAT) is not known.

Objective: To describe and compare disease course outcomes and morbidity among patients with moderate to severe pemphigus who received rituximab therapy (RT) in addition to prednisone and CAT, versus those who were treated with prednisone and CAT alone.

Methods: A 16-year retrospective case control study was designed with adult patients who were seen at the Duke University Dermatology Immunodermatology clinic from 1999-2015, who had a diagnosis of pemphigus vulgaris, and required prednisone and at least 1 systemic CAT. All patients had at least 6 months follow up from the initial visit. Interventions included RT, systemic CAT, and prednisone. The main outcome measured was prednisone intake. Secondary outcomes were complete remission (CR) and partial remission (PR).

Results: 40 patients were included in the study. All initially received prednisone and at least 1 systemic CAT. 13/40 eventually went on to receive RT, while 27/40 remained on CAT (CAT-only). Patients in the RT group, pre-RT, had a median prednisone intake of 658.57 mg/month. Rituximab treatment significantly reduced this to 177.22 mg/month (p = 0.002). Median prednisone intake of the CAT-only group was 141.33 mg/month. This was significantly less than Pre-RT (p = 0.01) and on par with Post-RT intake (p = 0.58). 54% of patients in the RT group and 64% of those in the CAT-only group achieved CR. All patients in the RT group and 96% of those in the CAT-only group achieved at least PR.

Conclusions: 32.5% of our patients with moderate to severe pemphigus vulgaris failed prednisone and traditional CAT treatment and required rituximab therapy. Rituximab reduced the monthly prednisone intake in these patients by 73%. This suggests that a subset of patients with moderate to severe pemphigus may benefit from early institution of rituximab therapy. Rituximab significantly reduces the monthly prednisone requirement among CAT-resistant pemphigus vulgaris patients to levels on par with CAT-responsive patients.

PubMed Disclaimer

Conflict of interest statement

I would like to affirm that I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Hall serves as consultant for and has received research grant support from Stiefel- a GSK Company and Syntimmune. He is a member of the data and safety monitoring board for Roche International, a member of the Eli Lilly Pemphigus Advisory Board and a consultant for Incyte and Principia. Dr. Cardones has received research grant support from Pfizer and is a consultant for Syntimmune. She is also a site investigator for Gilead. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patients.
Fig 2
Fig 2
(A). Cumulative prednisone intake among patients who received prednisone plus CAT who either failed and went on to receive rituximab (PRE-RITUXIMAB) or successfully remained on CAT only (CAT-only). Data graph and linear slope over 12 months (A), or the first 3 months only (B).
Fig 3
Fig 3. Number of infections requiring oral or IV therapy, hospitalization and ER visits, per patient year, among RT patients (pre and post-rituximab) and CAT-only.
See this image and copyright information in PMC

References

    1. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306(20):1189–96. 10.1056/NEJM198205203062001 . - DOI - PubMed
    1. Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Immunol Allergy Clin North Am. 2012;32(2):233–43, v-vi. 10.1016/j.iac.2012.04.003 . - DOI - PubMed
    1. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. Journal of the American Academy of Dermatology. 1996;34(4):645–52. 10.1016/S0190-9622(96)80066-1 - DOI - PubMed
    1. Schäcke H, Döcke W- D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics. 2002;96(1):23–43. 10.1016/S0163-7258(02)00297-8. - DOI - PubMed
    1. Parker SRS, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clinics in Dermatology. 2011;29(1):69–79. 10.1016/j.clindermatol.2010.07.010. 10.1016/j.clindermatol.2010.07.010 - DOI - DOI - PubMed

Publication types